The 2022 Drug Data Trends & National Benchmarks report by TELUS Health is a fan favorite filled with useful data. This year's report can be found here
TELUS shares that the growth rates for 2021 and 2020 occurred despite notable declines in the number of insureds who submitted claims during the first two years of the pandemic. So besides drug costs continuing to rise and should continue to be a focused area to reduce claim cost...
My Top 5 takeaways are:
It’s worth noting that Not all carriers followed suit to mimic the government’s switching policy in order to avoid taking on the full cost of originator biologics for plan members who choose not to switch and instead turn to their private plan for coverage. In addition to paying the full cost of a plan member’s claim, it also opens the Employer/Plan Sponsor to COB risk.
Comments are closed.